BIONOMICS says it will be proceeding with the next clinical trial of its tumour-treating BNC105 vascular disrupting agent in the US.
02/07/2009
TGEN CLINICAL Research Services at Scottsdale Healthcare has announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands
29/09/2009
LIVING Cell Technologies says New Zealand has authorised the Phase I/IIa clinical trial of DIABECELL for insulin dependent diabetes.
24/06/2009
LIVING Cell Technologies has formally opened its new designated pathogen free pig breeding facility in Invercargill, Southland, New Zealand.
02/07/2009
NEUREN Pharmaceuticals says it has obtained US$14m ($17.58m) of additional funding from the US Army, funding most of the costs for the upcoming NNZ-2566 Phase 2 trial.
03/07/2009
Brumby’s Labor Government has streamlined the ethical review process for clinical trials, making medical research into potentially lifesaving treatments easier to conduct in Victoria.
05/11/2009
PRANA Biotechnology says Dr Craig Ritchie of Imperial College, London, presented an update on the clinical efficacy of its PBT2 drug at the 2009 International Conference on Alzheimer’s Disease.
13/07/2009
PHARMACYCLICS has announced it is beginning treatment on patients in a Phase I dose-escalation study to evaluate the safety and tolerability of PCI-32765.
15/04/2009
WORLD COURIER has announced the opening of its newest purpose-driven investigational drug storage facilities in Melbourne and Johannesburg, bringing its network of GMP (Good Manufacturing Practice)-compliant clinical trial depots to a total of 11 worldwide and providing cost-effective logistical access to two continents critical to the global pharmaceutical industry.
15/10/2009
CSIRO has launched a new collaborative research cluster in Melbourne to establish a ‘biobank’ of blood samples to be used in advancing research into the prediction and early diagnosis of diseases such as Alzheimer’s and cancer.
19/02/2010
RESEARCHERS at TGen Clinical Research Service (TCRS) at Scottsdale Healthcare have analysed clinical trial results of potential new investigational therapy for advanced and metastatic basal cell skin cancer.
09/09/2009
CYTOPIA has filed an Investigational New Drug Application with the US Food and Drug Administration for its orally active JAK2 inhibitor CYT387.
24/06/2009
BRISBANE dermatology company Peplin has announced a definitive merger agreement whereby LEO Pharma (LEO) will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash.
07/09/2009
MICROSOFT has announced the winners of its 2009 Microsoft Pharmaceutical and Life Sciences Innovation Awards.
23/06/2009
A NEW DRUG designed to “seek and destroy” common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
06/10/2009
Purified human neural stem cells (HuCNS-SC) are being trialled to see if they can help treat neurodegenerative disorders that primarily afflict children.
24/11/2009
RESEARCHERS at the Austrian Breast & Colorectal Cancer Study Group (ABCSG) have found a bone metastases prevention drug reduces the risk of breast cancer recurrence in premenopausal women.
14/02/2009
PEPLIN has announced the initiation of two Phase III clinical trials to confirm the efficacy and safety of PEP005 (ingenol mebutate) Gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to head locations includuing the face and scalp
10/06/2009
PEPLIN says it has completed the enrolment of its two Phase 3 clinical trials for the use of PEP005 ingenol mebutate gel to treat actinic keratoses.
07/07/2009
LONZA and LFB have announced a joint agreement to manufacture a monoclonal anti-RhD antibody developed by LFB.
24/07/2009